Abstract
In a non-randomised study in six centres in the UK, 24 patients with previously untreated small-cell lung cancer of limited extent were treated with a regimen of alternating chemotherapy and radiotherapy to assess response, toxicity, and the feasibility of applying such a regimen on a multicentre basis in the UK. The intention was to give six courses of chemotherapy on five consecutive days at 4-week intervals: etoposide 75 mg m-2 on days 1, 2, and 3; doxorubicin 40 mg m-2 on day 1; cisplatin 100 mg m-2 on day 2; and cyclophosphamide 300 mg m-2 on days 2, 3, 4 and 5. A dose of 20 Gy thoracic radiotherapy was to be given following the 2nd and the 3rd courses, and one of 15 Gy following the 4th course. After 12 patients had been admitted, the cisplatin dosage was reduced to 80 mg m-2 because of unacceptable toxicity. Two patients were withdrawn during treatment on review of their histology because their diagnosis was found to be incorrect. Only one patient of the 12 treated with cisplatin 100 mg m-2 was able to complete treatment, compared with five of the eligible ten given the lower dosage. Among the 22 patients with confirmed small-cell disease, a complete response was reported in 14 (64%) and a partial response in a further three (total response rate 77%). Myelosuppression was the commonest serious adverse effect. It occurred in 19 of the 24 patients and gave rise to septicaemia in five, four of whom were receiving the higher cisplatin dose. Sixteen patients required blood transfusion and ten platelet transfusion. Vomiting, oesophagitis, and peripheral neuropathy occurred in 12, four and four patients, respectively, and radiation pneumonitis developed in two. Treatment was considered a contributory cause of death in four. The working party concluded that the alternating regimen was feasible in only a small proportion of centres in the UK, and decided not to embark on a multicentre randomised trial comparing alternating with conventional scheduling.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Arriagada R., Le Chevalier T., Baldeyrou P., Pico J. L., Ruffie P., Martin M., el Bakry H. M., Duroux P., Bignon J., Lenfant B. Alternating radiotherapy and chemotherapy schedules in small cell lung cancer, limited disease. Int J Radiat Oncol Biol Phys. 1985 Aug;11(8):1461–1467. doi: 10.1016/0360-3016(85)90333-5. [DOI] [PubMed] [Google Scholar]
- Bleehen N. M. Radiotherapy for small cell lung cancer. Chest. 1986 Apr;89(4 Suppl):268S–276S. doi: 10.1378/chest.89.4_supplement.268s. [DOI] [PubMed] [Google Scholar]
- Bunn P. A., Jr, Lichter A. S., Makuch R. W., Cohen M. H., Veach S. R., Matthews M. J., Anderson A. J., Edison M., Glatstein E., Minna J. D. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. A prospective, randomized trial. Ann Intern Med. 1987 May;106(5):655–662. doi: 10.7326/0003-4819-106-5-655. [DOI] [PubMed] [Google Scholar]
- Le Chevalier T., Arriagada R., Baldeyrou P., de Cremoux H., Ruffié P., Martin M., Cerrina M. L., de Thé G., Sancho-Garnier H., Hayat M. Association chimio-radiothérapique dans les carcinomes bronchiques à petites cellules. Limites et résultats chez 109 malades traites avec un schéma d'alternance. Bull Cancer. 1987;74(5):559–564. [PubMed] [Google Scholar]
- Leonard R. C. Small cell lung cancer. Br J Cancer. 1989 Apr;59(4):487–490. doi: 10.1038/bjc.1989.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rawson N. S., Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer. 1990 Apr;61(4):597–604. doi: 10.1038/bjc.1990.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Seifter E. J., Ihde D. C. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol. 1988 Jun;15(3):278–299. [PubMed] [Google Scholar]